Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its diverse product offerings and robust pipeline, Lilly is a far safer AI play than Recursion. 10 stocks we like better than Eli Lilly › Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug discovery process. The company, founded in 2013, has been working on that project since long before AI was the hottest topic on Wall Street. Despite its first-mover advantage and significant advances, Recursion Pharmaceuticals is facing competition that could hinder its efforts to dominate this niche. And one company that could become an even better healthcare AI leader is none other than Eli Lilly (NYSE: LLY) Image source: Getty Images. The industry's most powerful supercomputer Recursion Pharmaceuticals doesn't have any products on the market. In fact, none of the company's candidates are currently in phase 3 studie
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Lightning Round: Recursion Pharmaceuticals and NuScale Power [CNBC]CNBC
- Cramer's Lightning Round: Recursion Pharmaceuticals ‘has been horrendous' [CNBC]CNBC
- Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025GlobeNewswire
- Is Recursion Pharmaceuticals a Meme Stock? [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader? [Seeking Alpha]Seeking Alpha
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 144
- 12/2/25 - Form 144
- RXRX's page on the SEC website